Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine + Pemetrexed + Cisplatin in Mesothelioma and NSCLC
NCT02639091Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2016
- Primary completion
- May 2018
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of anetumab ravtansine in epithelial mesothelioma (EM) and Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose up to 2 years and Adverse Events up to 2 years. Started Feb 2016; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
epithelial mesothelioma (EM)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02639091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639091.